• Armando Silva-Almodóvar, Edward Hackim, Hailey Wolk, and Milap C Nahata.
• Institute of Therapeutic Innovations and Outcomes (ITIO), The Ohio State University College of Pharmacy, Columbus, OH, USA. silvaalmodovar.1@osu.edu.
• J Gen Intern Med. 2021 Aug 1; 36 (8): 2346-2352.

BackgroundPotentially inappropriately prescribed medications (PIPMs) among patients with chronic kidney disease (CKD) may vary among clinical settings. Rates of PIPM are unknown among Medicare-enrolled Medication Therapy Management (MTM) eligible patients.ObjectivesDetermine prevalence of PIPM among patients with CKD and evaluate characteristics of patients and providers associated with PIPM.DesignAn observational cross-sectional investigation of a Medicare insurance plan for the year 2018.PatientsMedicare-enrolled MTM eligible patients with stage 3-5 CKD.Main MeasuresPIPM was identified utilizing a tertiary database. Logistic regression assessed relationship between patient characteristics and PIPM.Key ResultsInvestigation included 3624 CKD patients: 2856 (79%), 548 (15%), and 220 (6%) patients with stage 3, 4, and 5 CKD, respectively. Among patients with stage 3, stage 4, and stage 5 CKD, 618, 430, and 151 were with at least one PIPM, respectively. Logistic regression revealed patients with stage 4 or 5 CKD had 7-14 times the odds of having a PIPM in comparison to patients with stage 3 disease (p < 0.001). Regression also found PIPM was associated with increasing number of years qualified for MTM (odds ratio (OR) 1.46-1.74, p ≤ 0.005), female gender (OR 1.25, p = 0.008), and increasing polypharmacy (OR 1.30-1.57, p ≤ 0.01). Approximately 14% of all medications (2879/21093) were considered PIPM. Majority of PIPMs (62%) were prescribed by physician primary care providers (PCPs). Medications with the greatest percentage of PIPM were spironolactone, canagliflozin, sitagliptin, levetiracetam, alendronate, pregabalin, pravastatin, fenofibrate, metformin, gabapentin, famotidine, celecoxib, naproxen, meloxicam, rosuvastatin, diclofenac, and ibuprofen.ConclusionOver one-third of Medicare MTM eligible patients with CKD presented with at least one PIPM. Worsening renal function, length of MTM eligibility, female gender, and polypharmacy were associated with having PIPM. Majority of PIPMs were prescribed by PCPs. Clinical decision support tools may be considered to potentially reduce PIPM among Medicare MTM-enrolled patients with CKD.© 2021. The Author(s).

17 keywords...

hide…